Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah‐Eddin Al‐Batran, Alexander Reichart, Nils Homann et al.|The Lancet|2019Cited by 2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Sebastian Stintzing, N. Niederle et al.|The Lancet Oncology|2014Cited by 1.7k
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerRonan J. Kelly, Markus Moehler|New England Journal of Medicine|2021Cited by 1.7k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al.|The Lancet|2018Cited by 1.3k
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialFlorian Lordick, Markus Moehler, Yoon‐Koo Kang et al.|The Lancet Oncology|2013Cited by 838